In the era of chimeric antigen receptor (CAR) T‐cell therapy for relapsed/refractory diffuse large B‐cell lymphoma (DLBCL), a new analysis from the Center for International Blood & Marrow Transplant Research (CIBMTR) confirms an ongoing role for autologous transplant in patients with chemosensitive relapsed DLBCL.